Cited by 60Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and AdiposityLiver Disease Diagnosis and Treatment

Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank

Open access
Tejani, Sanaa, McCoy, Cody, Ayers, Colby R., Powell-Wiley, Tiffany M., Després, Jean-Pierre, Linge, Jennifer, Leinhard, Olof Dahlqvist, Petersson, Mikael +2 more·2022·Mayo Clinic Proceedings

Abstract

Objective To evaluate the cardiometabolic outcomes associated with discordant visceral adipose tissue (VAT) and liver fat (LF) phenotypes in 2 cohorts. Patients and methods Participants in the Dallas Heart Study underwent baseline imaging from January 1, 2000, through December 31, 2002, and were followed for incident cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) through 2013. Associations between VAT-LF groups (low-low, high-low, low-high, and high-high) and outcomes were assessed using multivariable-adjusted regression and were replicated in the independent UK Biobank. Results The Dallas Heart Study included 2064 participants (mean ± SD age, 44±9 years; 54% female; 47% black). High VAT-high LF and high VAT-low LF were associated with prevalent atherosclerosis, whereas low VAT-high LF was not. Of 1731 participants without CVD/T2DM, 128 (7.4%) developed CVD and 95 (5.5%) T2DM over a median of 12 years. High VAT-high LF and high VAT-low LF were associated with increased risk of CVD (hazard ratios [HRs], 2.0 [95% CI, 1.3 to 3.2] and 2.4 [95% CI, 1.4 to 4.1], respectively) and T2DM (odds ratios [ORs], 7.8 [95% CI, 3.8 to 15.8] and 3.3 [95% CI, 1.4 to 7.8], respectively), whereas low VAT-high LF was associated with T2DM (OR, 2.7 [95% CI, 1.1 to 6.7]). In the UK Biobank (N=22,354; April 2014-May 2020), only high VAT-low LF remained associated with CVD after multivariable adjustment for age and body mass index (HR, 1.5 [95% CI, 1.2 to 1.9]). Conclusion Although VAT and LF are each associated with cardiometabolic risk, these observations demonstrate the importance of separating their cardiometabolic implications when there is presence or absence of either or both in an individual.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2021.08.021

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other ectopic fat depots, including liver fat, contribute to variations in health risk.

    “Other ectopic fat depots, including liver fat, also contribute to variations in health risk.50”

    From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [50]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. [1]Virani SS, Alonso A, Aparicio HJ, Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143: e254– e743. 33501848 PMC13036842
  2. [3]Cornier MA, Despres JP, Davis N, Assessing Adiposity: A Scientific Statement From the American Heart Association. Circulation. 2011; 124: 1996– 2019. 21947291
  3. [4]Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Molecular aspects of medicine. 2013; 34: 1– 11. 23068073 PMC3549425
  4. [5]Neeland IJ, Poirier P, Despres JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018; 137: 1391– 1406. 29581366 PMC5875734
  5. [6]Liu J, Fox CS, Hickson D, Bidulescu A, Carr JJ, Taylor HA. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011; 31(11): 2715– 22. 21885852 PMC3228266
  6. [7]Liu J, Fox CS, Hickson DA, Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. The Journal of clinical endocrinology and metabolism 2010; 95(12): 5419– 26. 20843952 PMC2999970
  7. [8]Linge J, Whitcher B, Borga M, Dahlqvist Leinhard O. Sub-phenotyping Metabolic Disorders Using Body Composition: An Individualized, Nonparametric Approach Utilizing Large Data Sets. Obesity (Silver Spring) 2019; 27(7): 1190– 9. 31094076 PMC6617760
  8. [9]Neeland IJ, Ross R, Despres JP, Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019; 7(9): 715– 25. 31301983
  9. [10]Victor RG, Haley RW, Willett DL, The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004; 93(12): 1473– 80. 15194016
  10. [11]Sudlow C, Gallacher J, Allen N, UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12(3): e1001779. 25826379 PMC4380465
  11. [12]Deo R, Khera A, McGuire DK, Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44(9): 1812– 8. 15519012
  12. [14]National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143– 421. 12485966
  13. [16]Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. The American journal of clinical nutrition 1997; 65(2): 403– 8. 9022523
  14. [17]Szczepaniak LS, Babcock EE, Schick F, Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276(5 Pt 1): E977– 89. 10329993
  15. [18]Borga M, Thomas EL, Romu T, Validation of a fast method for quantification of intraabdominal and subcutaneous adipose tissue for large-scale human studies. NMR in biomedicine 2015; 28(12): 1747– 53. 26768490
  16. [19]Linge J, Borga M, West J, Body Composition Profiling in the UK Biobank Imaging Study. Obesity (Silver Spring) 2018; 26(11): 1785– 95. 29785727 PMC6220857
  17. [20]West J, Dahlqvist Leinhard O, Romu T, Feasibility of MR-Based Body Composition Analysis in Large Scale Population Studies. PLoS One 2016; 11(9): e0163332. 27662190 PMC5035023
  18. [21]Borga M, Ahlgren A, Romu T, Widholm P, Dahlqvist Leinhard O, West J. Reproducibility and repeatability of MRI-based body composition analysis. Magn Reson Med 2020; 84(6): 3146– 56. 32519807
  19. [23]Neeland IJ, Ayers CR, Rohatgi AK, Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring, Md) 2013; 21(9): E439– 47. PMC3751977 23687099
  20. [24]Neeland IJ, Turer AT, Ayers CR, Body fat distribution and incident cardiovascular disease in obese adults. J Am Coll Cardiol 2015; 65(19): 2150– 1. 25975481 PMC4890465
  21. [26]Browning JD, Szczepaniak LS, Dobbins R, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387– 95. 15565570
  22. [27]Agbim U, Carr RM, Pickett-Blakely O, Dagogo-Jack S. Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. Curr Obes Rep 2019; 8(3): 243– 54. 31144261 PMC6662200
  23. [28]Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 65(3): 589– 600. 27212244
  24. [29]Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nature reviews Gastroenterology & hepatology 2017; 14(1): 32– 42. 27729660
  25. [30]Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature reviews Endocrinology 2011; 7(8): 456– 65. 21556019
  26. [31]Radaelli MG, Martucci F, Perra S, NAFLD/NASH in patients with type 2 diabetes and related treatment options. Journal of endocrinological investigation 2018; 41(5): 509– 21. 29189999
  27. [32]Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care 2018; 41(2): 372– 82. 29358469
  28. [33]Ballestri S, Zona S, Targher G, Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31(5): 936– 44. 26667191
  29. [34]Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7(4): 313– 24. 30174213

Cited by

Sorted by citations

Authors
Tejani, S., McCoy, C., Ayers, C. R., Powell-Wiley, T. M., Després, J.-P., Linge, J., Leinhard, O. D., Petersson, M., Borga, M., & Neeland, I. J.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Université Laval (CA)
  • Linköping University (SE)
  • Case Western Reserve University (US)
Corresponding author
Neeland, Ian J.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2022-02
Volume
97
Issue
2
Pages
225-237
ISSN
0025-6196 (ISSN-L)
OpenAlex
W3203948721
Cited by
60
References
6
Citations by year
2026: 10 · 2025: 14 · 2024: 11 · 2023: 17 · 2022: 8
FWCI
6.72
Type
journal article
Language
en
Open access
Locations
  • Mayo Clinic Proceedings (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Funders
  • National Center for Advancing Translational Sciences (UL1TR001105, VR-2019-04751)
  • Canadian Institutes of Health Research
  • Vetenskapsrådet
  • NIDDK
  • National Institute on Minority Health and Health Disparities
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • U.S. Department of Health and Human Services
  • University of Texas Southwestern Medical Center
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
visceral adipose tissue, liver fat, cardiometabolic risk, cardiovascular disease, type 2 diabetes, atherosclerosis, dyslipidemia, dyslipidemia severity, hepatic steatosis, visceral obesity, adipokines, adiponectin, leptin, adiponectin/leptin ratio
MeSH terms
Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fatty Liver, Female, United Kingdom, Humans, Male, Middle Aged, Phenotype, Risk Factors, Body Mass Index, Intra-Abdominal Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review